Harmony Biosciences Holdings (HRMY) — Capital Reinvestment Ratio

Latest as of December 2025: 0.00x

Harmony Biosciences Holdings (HRMY) has a Capital Reinvestment Ratio of 0.00x as of December 2025, meaning it reinvests 0% of its operating cash flow ($126.15 Million) in capital expenditures ($107.00K). Check HRMY intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.00x
Capex / Operating Cash Flow

Operating Cash Flow

$126.15 Million
USD

Capital Expenditures

$107.00K
USD

Data as of

Dec 2025
Most recent filing

Harmony Biosciences Holdings Capital Reinvestment Ratio (2021–2025)

This chart tracks Harmony Biosciences Holdings's Capital Reinvestment Ratio across 5 annual periods. For the full cash flow conversion analysis, see Harmony Biosciences Holdings cash conversion from operations.

Annual Capital Reinvestment Ratio for Harmony Biosciences Holdings (2021–2025)

Year-by-year Capital Reinvestment Ratio for Harmony Biosciences Holdings from 2021 to 2025. See HRMY FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2025 0.00x $348.20 Million $310.00K ▼ -83.0%
2024 0.01x $219.82 Million $1.15 Million ▲ +268.8%
2023 0.00x $219.39 Million $312.00K ▲ +19.4%
2022 0.00x $144.47 Million $172.00K ▼ -60.6%
2021 0.00x $98.56 Million $298.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow